{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:56:34Z","timestamp":1792788994559,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["VEO-000444"],"award-info":[{"award-number":["VEO-000444"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.vaccine.2024.126155","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T16:39:56Z","timestamp":1723653596000},"page":"126155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The quality-adjusted life-years loss due to serogroup B invasive meningococcal disease in Spain"],"prefix":"10.1016","volume":"42","author":[{"given":"Andrea","family":"Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Vallejo-Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najida","family":"Begum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Nikitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Gonz\u00e1lez-Inchausti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"de Gomensoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.126155_bb0005","author":"European Centre for Disease Prevention and Control"},{"key":"10.1016\/j.vaccine.2024.126155_bb0010","unstructured":"World Health Organization. Meningitis 2024 https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/meningitis [accessed Aug 08]."},{"key":"10.1016\/j.vaccine.2024.126155_bb0015","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJM200105033441807","article-title":"Meningococcal disease","volume":"344","author":"Rosenstein","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.126155_bb0020","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","article-title":"Epidemic meningitis, meningococcaemia, and Neisseria meningitidis","volume":"369","author":"Stephens","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.126155_bb0025","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/1471-2334-10-175","article-title":"The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology","volume":"10","author":"Racloz","year":"2010","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126155_bb0030","series-title":"Surveillance of invasive bacterial diseases in Europe, 2012: ECDC SURVEILLANCE REPORT","author":"European Centre for Disease Prevention and Control","year":"2015"},{"key":"10.1016\/j.vaccine.2024.126155_bb0035","series-title":"Short stay Management of Acute Heart Failure","author":"Peacock","year":"2017"},{"key":"10.1016\/j.vaccine.2024.126155_bb0040","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1186\/s12889-022-12933-3","article-title":"Epidemiology of invasive meningococcal disease and sequelae in the United Kingdom during the period 2008 to 2017 \u2013 a secondary database analysis","volume":"22","author":"Guedes","year":"2022","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2024.126155_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-022-13342-2","article-title":"Range of invasive meningococcal disease sequelae and health economic application\u2013a systematic and clinical review","volume":"22","author":"Shen","year":"2022","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2024.126155_bb0050","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S1474-4422(12)70180-1","article-title":"Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study","volume":"11","author":"Viner","year":"2012","journal-title":"The Lancet Neurology"},{"key":"10.1016\/j.vaccine.2024.126155_bb0055","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(16)31460-X","article-title":"Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2013;2015: a systematic analysis for the global burden of disease study 2015","volume":"388","author":"Kassebaum","year":"2016","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2024.126155_bb0060","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/13638490400022246","article-title":"Long-term psychological distress in parents of child survivors of severe meningococcal disease","volume":"8","author":"Ehrlich","year":"2005","journal-title":"Pediatr Rehabil"},{"key":"10.1016\/j.vaccine.2024.126155_bb0065","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/archpedi.162.11.1036","article-title":"Long-term health status in childhood survivors of meningococcal septic shock","volume":"162","author":"Buysse","year":"2008","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.vaccine.2024.126155_bb0070","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.jadohealth.2016.03.041","article-title":"Deciphering the burden of meningococcal disease: conventional and under-recognized elements","volume":"59","author":"Martin\u00f3n-Torres","year":"2016","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.vaccine.2024.126155_bb0075","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1741-3729.2010.00601.x","article-title":"Long-term effects of child death on parents\u2019 health-related quality of life: a dyadic analysis","volume":"59","author":"Song","year":"2010","journal-title":"Fam Relat"},{"key":"10.1016\/j.vaccine.2024.126155_bb0080","doi-asserted-by":"crossref","first-page":"S242","DOI":"10.1016\/j.jval.2018.09.2874","article-title":"PIN126 - the quality of life (QoL) loss associated with invasive meningococcal B disease (MenB) in Germany","volume":"21","author":"Scholz","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.vaccine.2024.126155_bb0085","author":"Ministerio de Ciencia Innovaci\u00f3n y Universidades"},{"key":"10.1016\/j.vaccine.2024.126155_bb0090","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1016\/j.vaccine.2014.07.019","article-title":"Costs of surviving meningococcal disease in Spain: evaluation for two cases of severe meningitis and septicaemia","volume":"32","author":"Darb\u00e0","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126155_bb0095","doi-asserted-by":"crossref","first-page":"5765","DOI":"10.1016\/j.vaccine.2011.05.089","article-title":"The burden of hospitalizations for meningococcal infection in Spain (1997-2008)","volume":"29","author":"Gil-Prieto","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126155_bb0100","doi-asserted-by":"crossref","first-page":"7646","DOI":"10.1016\/j.vaccine.2021.11.006","article-title":"Cost of illness of invasive meningococcal disease caused by serogroup B Neisseria meningitidis in Spain","volume":"39","author":"Ivanova-Markova","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126155_bb0105","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.anpede.2023.12.003","article-title":"Immunisation schedule of the Spanish Association of Pediatrics: 2024 recommendations","volume":"100","author":"\u00c1lvarez Garc\u00eda","year":"2024","journal-title":"Anales de Pediatr\u00eda (English Edition)"},{"key":"10.1016\/j.vaccine.2024.126155_bb0110","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.gaceta.2009.07.011","article-title":"Propuesta de gu\u00eda para la evaluaci\u00f3n econ\u00f3mica aplicada a las tecnolog\u00edas sanitarias","volume":"24","author":"L\u00f3pez Bastida","year":"2010","journal-title":"Gac Sanit"},{"key":"10.1016\/j.vaccine.2024.126155_bb0115","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/hec.3259","article-title":"Measuring health spillovers for economic evaluation: a case study in meningitis","volume":"25","author":"Al-Janabi","year":"2016","journal-title":"Health Econ"},{"key":"10.1016\/j.vaccine.2024.126155_bb0120","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g5725","article-title":"Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study","volume":"349","author":"Christensen","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2024.126155_bb0125","author":"Instituto Nacional de Estad\u00edstica"},{"key":"10.1016\/j.vaccine.2024.126155_bb0130","series-title":"Bolet\u00edn epidemiol\u00f3gico semanal","first-page":"35","article-title":"Enfermedad meningoc\u00f3cica. Temporadas 2018-2019, 2019-2020","volume":"29","author":"Soneira","year":"2021"},{"key":"10.1016\/j.vaccine.2024.126155_bb0135","author":"Instituto Nacional de Estad\u00edstica"},{"key":"10.1016\/j.vaccine.2024.126155_bb0140","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10198-018-0955-5","article-title":"Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries","volume":"20","author":"Janssen","year":"2019","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.vaccine.2024.126155_bb0145","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jval.2020.09.004","article-title":"Cost-effectiveness of 4CMenB infant vaccination in England: a comprehensive valuation considering the broad impact of serogroup B invasive meningococcal disease","volume":"24","author":"Beck","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.vaccine.2024.126155_bb0150","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40121-018-0213-2","article-title":"Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers","volume":"7","author":"Olbrich","year":"2018","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2024.126155_bb0155","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/INF.0000000000001048","article-title":"The burden of pediatric invasive meningococcal disease in Spain (2008-2013)","volume":"35","author":"Rivero-Calle","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2024.126155_bb0160","doi-asserted-by":"crossref","first-page":"S569","DOI":"10.1016\/j.jval.2020.08.995","article-title":"PIN154 QALY losses attributable to COVID-19 pandemic in Spain","volume":"23","author":"Hernando","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.vaccine.2024.126155_bb0165","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jval.2020.11.013","article-title":"Quality-adjusted life-year losses averted with every COVID-19 infection prevented in the United States","volume":"24","author":"Basu","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.vaccine.2024.126155_bb0170","author":"Centro Nacional de Epidemiolog\u00eda"},{"key":"10.1016\/j.vaccine.2024.126155_bb0175","unstructured":"Soneira MS, Alf\u00e9rez MDRC, Portero RC. Enfermedad meningoc\u00f3cica. Temporada 2020\u20132021. Vol. 30 n\u00b04 https:\/\/revista.isciii.es\/index.php\/bes\/article\/view\/1229 [accessed Oct 10]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24008181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24008181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T22:09:37Z","timestamp":1737583777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24008181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":35,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0264410X24008181"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126155","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The quality-adjusted life-years loss due to serogroup B invasive meningococcal disease in Spain","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126155","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 GSK. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126155"}}